Coya Therapeutics Q1 FY26 net loss narrows to $7.2 million

Coya Therapeutics, Inc.

Coya Therapeutics, Inc.

COYA

0.00
  • Coya Therapeutics posted a net loss of $7.2 million, or $0.32 per share, for quarter ended March 31, 2026.
  • Research and development expense fell to $4.1 million, while general and administrative expense climbed to $3.8 million.
  • Cash and cash equivalents totaled $50.7 million as of March 31, 2026.
  • FDA granted Fast Track designation to COYA 302 for ALS, while the IND for COYA 302 in frontotemporal dementia was accepted.
  • Management said ALSTARS Phase 2 trial is in full recruitment mode, maintaining guidance for a 1Q 2027 topline readout.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260512279103) on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.